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 Background The effect of prostate-specific antigen (PSA) screening on prostate cancer mortality remains debated, despite 
evidence from randomized trials. We investigated the association between prostate cancer incidence, reflecting 
uptake of PSA testing, and prostate cancer mortality.
Methods The study population consisted of all men aged 50 to 74 years residing in eight counties in Sweden with an early 
increase in prostate cancer incidence and six counties with a late increase during two time periods. Incidence of 
metastatic prostate cancer was investigated in the period from 2000 to 2009, and prostate cancer–specific mortal-
ity and excess mortality were investigated in the period from 1990 to 1999 and the period from 2000 to 2009 by 
calculating rate ratios for high- vs low-incidence counties and rate ratios for the period from 2000 to 2009 vs the 
period from 1990 to 1999 within these two groups. All statistical tests were two-sided.
Results There were 4 528 134 person-years at risk, 1577 deaths from prostate cancer, and 1210 excess deaths in men with 
prostate cancer in high-incidence counties and 2 471 373 person-years at risk, 985 prostate cancer deaths, and 
878 excess deaths in low-incidence counties in the period from 2000 to 2009. Rate ratios in counties with high vs 
low incidence adjusted for time period were 0.81 (95% confidence interval [CI] = 0.73 to 0.90) for prostate cancer– 
specific mortality and 0.74 (95% CI = 0.64 to 0.86) for excess mortality, and the rate ratio of metastatic prostate 
cancer was 0.85 (95% CI = 0.79 to 0.92).
 Conclusions The lower prostate cancer mortality in high-incidence counties reflecting a high PSA uptake suggests that more-
intense as compared with less-intense opportunistic PSA screening reduces prostate cancer mortality.
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The use of prostate-specific antigen (PSA) screening for detection 
of prostate cancer remains controversial. Two large, population-
based, randomized clinical trials—the European Randomized 
Study of Screening for Prostate Cancer (ERSPC) and the Göteborg 
trial—demonstrated 21% to 44% statistically significant decreases 
in prostate cancer–specific mortality after 11 to 14 years of follow-
up in screened vs unscreened men (1,2). In contrast, the prostate 
arm of the US Prostate, Lung, Colorectal, and Ovarian cancer 
screening trial (PLCO) found no benefit from systematic screen-
ing compared with opportunistic screening (3).
Thus, a controversy on PSA screening still remains, and in 
2012 the US Preventive Services Task Force recommended against 
screening, stating “there is moderate to high certainty that the 
benefits of PSA-based screening for prostate cancer [in terms of 
reduced prostate cancer mortality] do not outweigh the harm [in 
terms of overdiagnosis]” (4). This recommendation has been criti-
cized (5–7), and more data on the association between PSA screen-
ing and prostate cancer mortality are needed.
In addition to extended data from ERSPC and the Göteborg 
trial and the awaited results from the ongoing UK ProtecT trial, 
carefully designed and conducted observational population-based 
studies may provide valuable information on the association 
between PSA testing, early diagnosis, and treatment and prostate 
cancer mortality (8,9). Results from previous observational stud-
ies have been inconsistent; some studies have shown decreased 
prostate cancer mortality in areas with high PSA testing (10,11), 
whereas others have found no such difference (12,13).
In Sweden, as in many other Western countries, the introduc-
tion of PSA testing in the 1990s resulted in an increase in pros-
tate cancer incidence. Except for a randomized trial on systematic 
screening conducted in the city of Göteborg, the introduction 
of PSA testing was in the form of opportunistic screening (14). 
Among the 24 Swedish counties, there were large differences in 
prostate cancer incidence, with an estimated fourfold variation in 
the proportion of men undergoing PSA testing despite a uniform, 
equal-access health-care system (15).
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To capitalize on this natural experiment, we retrieved outcome 
data from three nation-wide, population-based registries in Sweden 
and assessed the incidence of metastatic prostate cancer, prostate can-
cer–specific mortality, and excess mortality in counties with an early 
increase in the incidence of prostate cancer and in counties with a late 
increase, reflecting differences in uptake of PSA testing, to investigate 
the association between PSA testing and prostate cancer mortality.
Methods
The Swedish Cancer Register, Cause of Death Register, 
and National Prostate Cancer Register
Swedish law mandates and regulates the registration of incident can-
cer cases in the Swedish Cancer Register and deaths in the Cause of 
Death Register. The Cancer Register contains each patient’s 10-digit 
personal identity number, date of diagnosis, county of residence, and 
cancer site. The Cause of Death Register contains the personal iden-
tity number, date of death, and underlying and contributory causes 
of death. Since 1998, approximately 98% of all incident prostate 
cancer cases in the Swedish Cancer Register were also registered in 
the National Prostate Cancer Register, including the reason for the 
work-up that led to diagnosis, tumor stage, Gleason score, serum 
PSA at time of diagnosis, and primary treatment (16,17).
Identification of Prostate Cancer Case Patients and 
Endpoints
We used the Swedish Cancer Register to identify prostate cancer case 
patients diagnosed from January 1, 1980, to December 31, 2009, and 
linked by personal identity numbers (18) to the National Prostate 
Cancer Register to obtain information on metastases at the time of 
diagnosis, evidenced by radiographic evaluation (bone scans) for the 
large majority of men or serum PSA levels greater than 100 ng/mL 
(16). We obtained date and cause of death by linkage to the Swedish 
Cause of Death Register for death attributed to prostate cancer when 
it was coded as “underlying cause of death.” The study was approved 
by the Research Ethics Board at Umeå University Hospital.
Statistical Analysis
We calculated the predicted prostate cancer incidence—that is, the 
incidence that would be expected if no PSA testing had occurred. 
Because PSA testing was introduced in clinical practice in Sweden 
in the 1990s, the prediction for each year up to 2009 was based on 
the observed incidence for the period from 1980 to 1990. We used 
a linear regression model with a common slope for calendar year 
but separate intercepts for each county. Age-adjusted prostate can-
cer incidence for men aged 50 to 74 years was calculated by direct 
standardization with weights from the Swedish population census 
of 2000 (19). We then calculated the cumulative difference between 
the observed and predicted age-adjusted prostate cancer incidence 
in men aged 50 to 74 years starting from 1995 and found a range 
of −126 per 100 000 to 1634 per 100 000. We used this difference 
to categorize counties as having high, intermediate, or low prostate 
cancer incidence and chose the cutoffs of 100 per 100 000 between 
low- and intermediate-incidence counties and 800 per 100 000 
between intermediate- and high-incidence counties.
We used two measures of prostate cancer mortality—prostate can-
cer–specific mortality, which was based on the underlying cause of death 
given in the Cause of Death Register (20,21), and excess mortality (22), 
based on the excess number of deaths (observed minus expected) regard-
less of cause of death among men with prostate cancer. We calculated 
the expected number of deaths as the product of person-years among 
the incident prostate cancer case patients and the total mortality rate 
in the population, calculated per year and per attained age in groups of 
5 years. We determined prostate cancer mortality during two calendar 
periods, 1990 to 1999 and 2000 to 2009. We calculated incidence-based 
mortality for each of the mortality measures based on deaths among 
men diagnosed with prostate cancer during the study period (20,21). In 
addition, we calculated the 2000 to 2009 incidence of metastatic prostate 
cancer (23). To determine incidence and mortality rates, we used person-
years based on population statistics by year and by 5-year age group. All 
rates were measured at the population level (with the male population, 
not the number of men with prostate cancer as denominator).
We calculated rate ratios (RRs) for high- vs low-incidence coun-
ties and the rate ratios for the period from 2000 to 2009 vs the period 
from 1990 to 1999 within these two groups. Finally we also deter-
mined rate ratios for high- vs low-incidence counties adjusted for 
time period by dividing by the corresponding rate ratio in the period 
from 1990 to 1999. We calculated rate ratios for men aged 50 to 
74 years and the subgroup aged 55 to 69 years, which was the core 
age group in the ERSPC study (24). We based confidence intervals 
(CIs) on the assumption of a Poisson distribution of the number of 
events and calculated variances using the delta method on the loga-
rithm of the estimates followed by normal approximation (25).
results
Between 1980 and 2009, 197 014 Swedish men aged 50 to 74 years 
were diagnosed with prostate cancer, and of those, 6900 men with 
noninvasive or secondary prostate cancers were excluded from the 
study. Figure 1 presents a flow chart of the study cohort.
There were 4 528 134 person-years at risk, 1577 deaths from 
prostate cancer, and 1210 excess deaths in men with prostate cancer 
in high-incidence counties and 2 471 373 person-years, 985 pros-
tate cancer deaths, and 878 excess deaths in low-incidence coun-
ties in the period from 2000 to 2009. A rapid increase in prostate 
cancer incidence began in some counties in 1990 but not until 
10 years later in other counties (Figure 2A). Figure 2B shows the 
cumulative difference between observed and predicted prostate 
cancer incidence in each county from 1995 to 2009. The differ-
ence in incidence between the high- and low-incidence counties 
was largest in 2005 and decreased thereafter, disappearing in 2009 
(Supplementary Figure 1, available online).
In the period from 2000 to 2009, the cumulative incidence of 
metastatic disease, prostate cancer–specific mortality, and excess 
mortality was statistically significantly lower in high-incidence 
counties than in low incidence counties (Figure 3, A–C), with rate 
ratios of 0.85 (95% = 0.79 to 0.92) for metastatic disease, 0.87 (95% 
CI = 0.81 to 0.95) for prostate cancer–specific mortality, and 0.75 
(95% CI = 0.66 to 0.86) for excess mortality (Figure 4A).
In high-incidence counties, prostate cancer–specific mortaliy 
and excess mortality were statistically significantly lower dur-
ing the period from 2000 to 2009 than during the period from 
1990 to 1999, and we observed similar, albeit somewhat weaker 
differences in low-incidence counties (Figure 4B). When taking 
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both county group and time period into consideration, the differ-
ences in cancer-specific mortality and excess mortality between 
high- vs low-incidence counties remained statistically significant 
(Figure 4C). The rate ratios adjusted for time period for high- vs 
low-incidence counties were 0.81 (95% CI  =  0.73 to 0.90) for 
prostate cancer–specific mortality and 0.74 (95% CI  =  0.64 to 
0.86) for excess mortality, and the rate ratios for the subgroup of 
men aged 55 to 69 years were similar. The estimated rate ratio of 
prostate cancer specific mortality of 0.81 would correspond to an 
annual absolute reduction at 0.23 per 1000 men when applied to 
the Swedish prostate cancer mortality year 2000 in the age group 
55 to 79 years.
Data in the National Prostate Cancer Register from 2000 
to 2009 indicated that diagnostic and therapeutic activity was 
higher in high-incidence counties than in low-incidence counties 
(Table 1). In the high-incidence counties, median age at diagno-
sis was lower, a higher proportion of men had low-risk cancer 
(clinical stage T1–T2, Gleason score 2–6, and PSA < 10 ng/mL at 
diagnosis), a higher proportion underwent radical prostatectomy, 
and median serum PSA at diagnosis was lower. The difference 
between high- vs low-incidence counties in diagnostic PSA levels 
was largest in 2000 (10.0 vs 17.6 ng/mL) and decreased steadily 
after that (Supplementary Table 1, available online). The use of 
radiotherapy and radical prostatectomy showed similar temporal 
trends with the highest use in high-incidence counties and with a 
decreasing difference over time (Supplementary Figure 2, avail-
able online).
Discussion
In this register-based, population-based study in Sweden, incidence 
of metastatic prostate cancer was 15% lower, and prostate cancer–
specific mortality and excess mortality adjusted for time period 
were 19% and 26% lower, respectively, in counties with high vs 
low incidence of prostate cancer, reflective of early vs late uptake of 
PSA testing. These results suggest that opportunistic PSA screen-
ing decreases prostate cancer mortality.
The strength of our study lies in its population-based design, its 
magnitude, the completeness of the registers, and the equal access 
health care in the two study groups. It covered nearly 7 million 
person-years at risk and 2562 prostate cancer deaths registered 
between 2000 and 2009 and had the power to detect moderately 
strong associations between PSA testing and prostate cancer death. 
Furthermore, PSA testing is likely to be particularly effective in 
Sweden because prostate cancer mortality is higher in Sweden than 
in other countries, with a lifetime risk of prostate cancer death of 
5% to 6%, so Swedish men with prostate cancer are at high risk of 
disease progression (26). Other strengths of our study were the use 
of incidence-based mortality, which enabled us to avoid diluting 
risk estimates by including deaths among men diagnosed before 
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Figure 1. Flow chart of linkages between the Swedish Cancer Register, the Swedish Cause of Death Register, and the National Prostate Cancer Register 
of Sweden and final study population. * Distant metastasis defined as M1 and/or prostate-specific antigen ≥ 100 ng/mL.
======= indicates registry linkage.
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Figure  2. Counties ranked by the cumulative difference between 
observed and predicted prostate cancer incidence per 100 000 from 
1995 through 2002. A) Observed and predicted age-standardized 
prostate cancer incidence in men aged 50–74  years in 24 Swedish 
counties during the period from 1980 to 2009. Steady line is pre-
dicted incidence, and undulating line is observed incidence. B) 
Cumulative difference between observed and predicted incidence of 
prostate cancer during the period from 1995 to 2009. Negative differ-
ences resulting from the predicted incidence being higher than the 
observed incidence in low-incidence counties were set to zero. G & 
B = Göteborg and Bohus county; H = high-incidence county; L = low 
incidence county.
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Figure 3. Prostate cancer incidence and mortality in men in Sweden aged 50 to 74 years, 2000 to 2009. A) Cumulative incidence of metastatic dis-
ease. B) Prostate cancer-specific mortality. C) Excess mortality.
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Figure 4. Risk of prostate cancer mortality according to county of resi-
dency (in groups of counties with high and low incidence) and time 
period in groups of counties with high, intermediate and low incidence of 
prostate cancer A) Rate ratio (RR) of incidence of metastatic prostate can-
cer, prostate cancer–specific mortality, and excess mortality in high- vs 
low-incidence counties. B) Rate ratio of prostate cancer–specific mortality 
and excess mortality in the period from 2000 to 2009 vs the period from 
1990 to 1999. C) Rate ratio for high- vs low-incidence group adjusted for 
time period. * Metastatic prostate cancer defined as M1 and/or prostate-
specific antigen ≥ 100 ng/mL at diagnosis. ** Excess mortality defined as 
the excess number of deaths (observed minus expected), regardless of 
cause of death among men with prostate cancer. CI = confidence interval.
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the introduction of PSA testing, and the use of three separate end-
points—incidence of metastatic prostate cancer, prostate cancer-
specific mortality, and excess mortality.
The Swedish Cancer Register captures 96% of all cancer 
diagnoses, and the capture rate is particularly high for solid 
tumors and in subjects aged less 70 years (27). The validity of the 
Cause of Death Register is high for prostate cancer. For exam-
ple, in the Göteborg screening trial, there was a 96% agreement 
between a chart review of death certificates and the Cause of 
Death Register (28), and in another study with a wider range 
in stage and grade, the agreement was 86% (29). Besides pros-
tate cancer–specific mortality, we also investigated the incidence 
of metastatic prostate cancer, which was the first indication of 
the efficacy of PSA screening in the European trials (1,2). We 
assessed the occurrence of metastatic disease at date of diagnosis 
by use of data on the presence of bone metastases or a serum 
level greater than 100 ng/mL available from 2000 in the National 
Prostate Cancer Register.
Our study also had some limitations because we were unable to 
directly measure the extent of PSA testing in the population. Instead, 
we used the difference between the observed and predicted cumula-
tive incidence of prostate cancer under the assumption that a high 
incidence indicated an early introduction and a high prevalence of 
PSA testing with ensuing early prostate cancer diagnosis and treat-
ment. This assumption was corroborated by data in the National 
Prostate Cancer Register on distribution of risk categories with lower 
median serum PSA levels at diagnosis, higher proportion of clinically 
localized low-risk cancers, higher proportion of curative treatments, 
and a lower age at diagnosis in high- vs low-incidence counties.
Geographical comparisons can be hampered by differences in 
baseline risk, and prior observational studies comparing high and 
low prostate cancer incidence areas in the United States reported 
no difference in prostate cancer mortality (12,13). In the first time 
period of our study, prostate cancer–specific mortality was higher 
in high-incidence counties than in low-incidence counties, showing 
that the subsequently lower prostate cancer mortality in high-inci-
dence counties was not simply the result of differences in baseline 
risk. Temporal comparisons can be hampered by changes in diagnos-
tic criteria over time and thus can also be affected by bias. To address 
these issues, we made separate geographical and temporal compari-
sons and used a combined approach as well, including adjustment 
for time periods in the analysis of geographical differences.
Our risk estimates were affected by other sources of bias. The 
decrease in excess mortality was consistently larger than the decrease 
in prostate cancer–specific mortality. Excess mortality likely overes-
timates the benefit of screening because it reflects a lower mortality 
from causes other than prostate cancer. There may be selection bias 
for healthy Swedish men with a long life expectancy who undergo 
PSA testing and early detection, as suggested in a previous study 
in the National Prostate Cancer Register, which showed lower 
10-year all-cause mortality among men with low- and intermedi-
ate-risk prostate cancer compared with the background population, 
indicating a healthy screenee effect (30). In contrast, prostate can-
cer–specific mortality underestimates the risk reduction because it 
Table 1. Characteristics of men aged 50 to 74 years with prostate cancer in the National Prostate Cancer Register of Sweden, 2000 to 2009*
Characteristic
County Incidence
High (n = 33 780) Intermediate (n = 37 624) Low (n = 16 377)
Age at diagnosis, y
 Median (IQR) 70 (63–77) 70 (63–77) 72 (65–79)
 Mean (SD) 70.0 (9.3) 70.2 (9.2) 71.7 (9.1)
Serum PSA level, ng/mL
 Median (IQR) 10.8 (6.0–27.0) 12.0 (6.6–32.0) 15.0 (7.6–43.0)
 No. missing (%) 506 (1.5) 1114 (3.0) 385 (2.4)
Mode of detection, No. (%)
 PSA testing as a part of health check-up 10 684 (31.6) 10 101 (26.8) 3646 (22.3)
 Lower urinary tract symptoms 10 533 (31.2) 10 668 (28.4) 5793 (35.4)
 Other symptoms/unknown 12 563 (37.2) 16 855 (44.8) 6938 (42.4)
Planned treatment, No. (%)†
 Surveillance 8937 (26.5) 8613 (22.9) 4079 (24.9)
 Radical prostatectomy 8444 (25.0) 8425 (22.4) 2419 (14.8)
 Radiation therapy 4198 (12.4) 4891 (13.0) 2501 (15.3)
 Hormonal therapy 10 931 (32.4) 12 600 (33.5) 6620 (40.4)
 Other/missing 1270 (3.8) 3095 (8.2) 758 (4.6)
Risk category, No. (%)‡
 Low risk 9874 (29.2) 9593 (25.5) 3366 (20.6)
 Intermediate risk 8651 (25.6) 8997 (23.9) 3867 (23.6)
 High risk 7908 (23.4) 9917 (26.4) 4570 (27.9)
 Regionally metastatic 2097 (6.2) 2735 (7.3) 1407 (8.6)
 Distant metastases 4524 (13.4) 5158 (13.7) 2891 (17.7)
 Missing 726 (2.1) 1224 (3.3) 276 (1.7)
* IQR = interquartile range; PSA = prostate-specific antigen; SD = standard deviation.
† Initiated or planned within the 6 months after diagnosis.
‡ Risk groups according to modification of the National Comprehensive Cancer Network. Low risk: T1 to 2, Gleason score 2 to 6, and PSA < 10 ng/mL. Intermediate 
risk: T1 to 2, Gleason score 7, and/or PSA 10 to <20 ng/mL. High risk: T3, and/or Gleason score 8 to 10, and/or PSA 20 to <50 ng/mL. Regionally metastatic disease: 
T4 and/or N1 and/or PSA 50 to <100 ng/mL in the absence of distant metastases (M0 or Mx). Distant metastases: M1 and/or PSA ≥100 ng/mL.
JNCI | Article 8 of 9jnci.oxfordjournals.org
is affected by attribution bias; death from an uncertain cause is more 
likely attributed to prostate cancer in men with a prostate cancer 
diagnosis than in other men (31). Furthermore, our follow-up time 
was 10 years at maximum, which is likely too short a time to reap 
the full effect of early detection. Finally, confounding by unknown 
factors cannot be ruled out. Despite these shortcomings, a higher 
incidence of prostate cancer was consistently associated with lower 
risk estimates in all 18 risk analyses.
The ERSPC study, the largest randomized screening trial to 
date with 761 prostate cancer deaths, showed virtually the same 
reduction (21%) in mortality observed after 11 years of follow-up 
as our study (1). In the Göteborg screening trial in Sweden, based 
on 122 prostate cancer deaths, a larger reduction in mortality was 
observed (44%), likely because of the longer median follow-up of 
14 years. Speculatively, the larger effect in the Göteborg trial com-
pared with our observations may, in addition to a longer follow-up, 
also be because of a more stringent work-up of men with elevated 
serum PSA in a trial setting and to a superior diagnostic and ther-
apeutic level of care in a high-volume setting as compared with 
our results that were based on routine clinical practice among all 
health-care providers in 14 Swedish counties.
Our results from a population-based, real-life study indicate 
that more-intense as compared with less-intense opportunistic 
PSA screening decreases prostate cancer mortality, which recon-
ciles the findings of the two largest trials on PSA screening to date, 
namely ERSPC (organized vs no screening) and PLCO (organized 
vs opportunistic screening) and is congruent with the reduction of 
prostate cancer mortality that has occurred in the United States 
during the last decades, during which time period early diagnosis 
and early treatment has increased drastically (32).
However, opportunistic screening as it is currently imple-
mented in real life is inefficient and is implemented too frequently 
in the wrong age groups. In a recent Swedish study, 6% of men 
aged 40 to 49 years, 16% of men age 50 to 59 years, 27% of men 
aged 60 to 69 years, 30% of men aged 70 to 79 years, and 23% 
of men age 80 to 89 years had an annual PSA test (33), whereas 
in the United States, 45% of men aged 75 years and older have a 
yearly PSA test (34). The frequent PSA testing of older men leads 
to overdetection and overtreatment, and to maximize the benefits 
while at the same time minimizing the adverse effects of screening 
and ensuing treatment, risk-stratified screening with regular but 
infrequent PSA testing of middle-aged men holds promise (35).
In conclusion, in our population-based study we observed lower 
incidence of metastatic prostate cancer, lower prostate cancer–spe-
cific mortality, and lower excess mortality in counties with high 
vs low incidence of prostate cancer, reflecting PSA uptake. This 
indicates that more-intense as compared with less-intense oppor-
tunistic PSA screening reduces prostate cancer mortality.
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